News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation to Double Respimat Soft Inhalers Production With $110 Million Investment, to Hire 100



10/30/2012 7:32:27 AM

Boehringer Ingelheim Pharmaceuticals | Jobs at Boehringer Ingelheim Pharmaceuticals

In view of increasing demand for innovative inhalation system, the research-driven pharma company - Boehringer Ingelheim Corporation is investing approximately Euro 85 million ($110 Million) in its Dortmund facility to double the Respimat soft inhalers production to 44 million annually by 2015. Will add 100 to Headacount, According to Sources.

A successful treatment of respiratory diseases depends on how much of the active substance enters into the patient's lung. Boehringer Ingelheim's Respimat soft inhaler and its long-lasting aerosol cloud effectively transport the active substance into the patient's lung.

Read at PharmaBiz


comments powered by Disqus
PharmaBiz
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES